ARS Pharmaceuticals: Strategic Developments and Market Opportunities Drive Buy Rating for Neffy

Analyst Roanna Ruiz of Leerink Partners reiterated a Buy rating on ARS Pharmaceuticals (SPRY – Research Report), with a price target of $27.00.

Roanna Ruiz’s rating is based on several strategic developments and market opportunities for ARS Pharmaceuticals. The FDA’s approval of neffy 1 mg for a younger pediatric segment expands the drug’s market potential significantly, especially as it aligns with the seasonal increase in epinephrine prescriptions during the back-to-school period. This approval is expected to boost neffy’s U.S. launch revenues in the coming quarters, a factor that may not yet be fully appreciated by investors.
Additionally, ARS Pharmaceuticals has made strides in securing broader and more favorable payer coverage for neffy, which is likely to enhance its market penetration. The company’s initiatives to increase awareness among key opinion leaders, physicians, and patients, coupled with plans for a direct-to-consumer campaign, are poised to strengthen neffy’s market position. These efforts, along with the drug’s positive reception at a recent medical conference, create a promising outlook for neffy’s growth and justify the Buy rating.

SPRY’s price has also changed slightly for the past six months – from $11.360 to $10.790, which is a -5.02% drop .